FDA Refines Guidance On Immunogenicity Testing
Executive Summary
FDA’s final guidance on the development of assays used in clinical trials to evaluate the immunogenicity of therapeutic proteins provides more detail on where immunogenicity information is to be placed in BLAs, and adds appendix on a multi-tiered approach to anti-drug antibody testing.